Contineum Therapeutics, Inc. (CTNM) quarterly cash flow statement — complete operating, investing & financing history
Contineum Therapeutics, Inc. (CTNM) cash flow statement — 5-year operating, investing & financing cash flows
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 |
|---|
| Cash from Operations | -11.5M | -16.27M | -13.04M | -12.2M | -15.66M | -14.41M | -10.2M | -6.17M | -8.36M | -8.12M | -10.7M | -5.38M | -5.24M | -4.08M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 26.56% | -12.86% | -27.84% | -97.71% | -87.35% | -77.6% | 4.69% | -14.73% | - | -54.75% | -162.55% | - | - | - |
| Net Income | -15.15M | -14.46M | -15.16M | -12.79M | -16.04M | -15.99M | -14.56M | -10.27M | -9.01M | -8.42M | -7.77M | -6.25M | -4.82M | -7.51M |
| Depreciation & Amortization | 134K | 83K | 85K | 81K | 79K | 78K | 75K | 62K | 60K | 61K | 37K | 43K | 73K | 81K |
| Stock-Based Compensation | 3.84M | 3.82M | 2.48M | 2.57M | 2.42M | 2.57M | 2.25M | 2.29M | 1.49M | 768K | 759K | 477K | 494K | 491K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -330K | 231K | 278K | 237K | -184K | 13K | -913K | -573K | 799K | -34K | -941K | -765K | 27K | 2.44M |
| Working Capital Changes | 9K | -5.95M | -731K | -2.29M | -1.93M | -1.08M | 2.95M | 2.32M | -209K | 275K | -2.79M | 1.12M | -1.01M | 419K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -990K | 490K | 162K | -1.22M | -1.64M | 1.83M | 378K | 663K | 170K | -70K | -625K | 656K | 282K | 23K |
| Cash from Investing | 4.85M | -39.31M | -47.45M | 14.94M | 13.88M | 14.91M | -9.39M | -30.18M | -38.9M | 8.73M | 9.03M | -39.5M | 9.36M | 4.92M |
| Capital Expenditures | -6K | -312K | -42K | -98K | -44K | -47K | -166K | -82K | -119K | -147K | -309K | -22K | -52K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.2M | 129K | 93.47M | 19.11M | 91K | 24K | 642K | 13K | 108.22M | 122K | -321K | 10.32M | -617K | -625K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -625K | -625K |
| Equity Issued (Net) | 1.25M | 198K | 93.47M | 19.01M | 267K | 24K | 642K | 13K | 108.22M | 122K | 1K | 10.21M | 8K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 0 | 0 | 0 |
| Other Financing | -53K | -69K | 0 | 93K | -176K | 0 | 0 | 0 | 0 | 0 | -322K | 111K | 0 | 0 |
| Net Change in Cash | -5.45M | -55.45M | 32.97M | 21.85M | -1.69M | 527K | -18.95M | -36.34M | 60.97M | 738K | -2M | -34.55M | -5.57M | 215K |
| Free Cash Flow | -11.51M | -16.58M | -13.08M | -12.29M | -15.71M | -14.46M | -10.37M | -6.25M | -8.48M | -8.26M | -11.01M | -5.4M | -5.3M | -4.08M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 26.73% | -14.66% | -26.2% | -96.69% | -85.24% | -75.01% | 5.86% | -15.78% | - | -56% | -170.13% | - | - | - |
| FCF per Share | -0.31 | -0.44 | -0.42 | -0.44 | -0.61 | -0.56 | -0.40 | -0.24 | -0.33 | -0.32 | -0.44 | -0.21 | -0.21 | -0.16 |
| FCF Conversion (FCF/Net Income) | 0.76x | 1.13x | 0.86x | 0.95x | 0.98x | 0.90x | 0.70x | 0.60x | 0.93x | 0.96x | 1.38x | 0.86x | 1.09x | 0.54x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |